Castleark Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-69,720
Closed -$3.99M 303
2024
Q3
$3.99M Buy
+69,720
New +$4M 0.16% 137
2024
Q1
Sell
-115,894
Closed -$4.28M 296
2023
Q4
$4.28M Sell
115,894
-11,856
-9% -$447K 0.19% 130
2023
Q3
$4.88M Buy
+127,750
New +$5.23M 0.25% 97
2023
Q1
Sell
-205,680
Closed -$11.7M 301
2022
Q4
$11.7M Sell
205,680
-11,070
-5% -$567K 0.61% 37
2022
Q3
$8.57M Buy
216,750
+12,810
+6% +$566K 0.48% 44
2022
Q2
$8.97M Buy
+203,940
New +$8.82M 0.48% 37
2021
Q4
Sell
-219,787
Closed -$8.94M 345
2021
Q3
$8.94M Sell
219,787
-98,000
-31% -$4.1M 0.34% 82
2021
Q2
$14.4M Sell
317,787
-112,815
-26% -$4.99M 0.48% 45
2021
Q1
$18M Sell
430,602
-68,540
-14% -$3.13M 0.65% 39
2020
Q4
$21.3M Sell
499,142
-99,475
-17% -$3.58M 0.8% 32
2020
Q3
$15.7M Buy
598,617
+37,432
+7% +$1.04M 0.62% 41
2020
Q2
$15M Buy
561,185
+123,315
+28% +$2.78M 0.65% 37
2020
Q1
$7.88M Buy
+437,870
New +$8.31M 0.47% 58
2018
Q3
Sell
-423,305
Closed -$7.14M 389
2018
Q2
$7.14M Sell
423,305
-9,579
-2% -$181K 0.22% 147
2018
Q1
$8.48M Buy
432,884
+82,529
+24% +$1.6M 0.27% 117
2017
Q4
$7.1M Buy
350,355
+117,450
+50% +$2.16M 0.21% 150
2017
Q3
$4.05M Buy
+232,905
New +$3.15M 0.13% 207

Other funds holding HALO

Castleark Management's HALO Position: Q4 2024 in Review

Castleark Management sold out of Halozyme (HALO) in Q4 2024, closing a stake of 69,720 shares — an estimated $3.99M sold.

Castleark Management first reported a position in HALO in Q3 2017 and held it in 17 quarters. The position peaked at $21.3M in Q4 2020. 508 funds tracked by Wall St. Rank hold HALO as of Q4 2024.

  • Castleark Management reported no remaining Halozyme position as of Q4 2024 after selling out during the quarter.
  • Castleark Management sold 69,720 Halozyme shares in Q4 2024, an estimated $3.99M.
  • Castleark Management first reported a position in Halozyme in Q3 2017 and held it in 17 quarters.
  • Castleark Management's Halozyme position peaked at $21.3M in Q4 2020.
  • 508 funds tracked by Wall St. Rank held Halozyme as of Q4 2024.

Based on Castleark Management's 13F filing for Q4 2024, filed 18 Feb 2025.